Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms PAISLEY
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 15 Nov 2023 Results exploring whether patients could sustain CLASI-50 over time and achieve 100% reduction in CLASI activity were presented at the ACR Convergence 2023.
    • 15 Nov 2023 Results of transcriptomic analysis of patients treated with DEUC to further explore the mechanism of action (MOA) and effects of DEUC in SLE, presented at the ACR Convergence 2023
    • 15 Nov 2023 Results of post hoc analysis assessing efficacy, time to response, and sustained responses over 48 Weeks of deucravacitinib comparing with placebo in systemic lupus erythematosus, presented at the ACR Convergence 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top